Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
We conducted a single-institution phase II clinical trial evaluating the safety and
efficacy of combination chemoimmunotherapy followed by radioimmunotherapy consolidation
and rituximab maintenance as front-line treatment in indolent lymphomas.